Once-daily oral icotrokinra outperforms placebo in ulcerative colitis
For patients with moderately to severely active ulcerative colitis, oral icotrokinra, a peptide that blocks the interleukin-23 receptor, yields a clinical response at week 12 significantly more often ...
24 Oct 02:00 · Medical Xpress